Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations - PubMed (original) (raw)
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations
Gudrun Pohl et al. Cancer Res. 2005.
Abstract
Activation of mitogen-activated protein kinase (MAPK) occurs in response to various growth stimulating signals and as a result of activating mutations of the upstream regulators, KRAS and BRAF, which can be found in many types of human cancer. To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that selectively inhibits MAPK kinase, an upstream regulator of MAPK and thus prevents MAPK activation. Profound growth inhibition and apoptosis were observed in CI-1040-treated tumor cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences. Long serial analysis of gene expression identified several differentially expressed genes in CI-1040-treated MPSC1 cells harboring an activating mutation in BRAF (V599L). The most striking changes were down-regulation of cyclin D1, COBRA1, and transglutaminase-2 and up-regulation of tumor necrosis factor-related apoptosis-induced ligand, thrombospondin-1, optineurin, and palladin. These patterns of gene expression were validated in other CI-1040-treated tumor cells based on quantitative PCR. Constitutive expression of cyclin D1 partially reversed the growth inhibitory effect of CI-1040 in MPSC1 cells. Our findings indicate that an activated MAPK pathway is critical in tumor growth and survival of ovarian tumors with KRAS or BRAF mutations and suggest that the CI-1040 induced phenotypes depend on the mutational status of KRAS and BRAF in ovarian tumors.
Similar articles
- Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM. Hsu CY, et al. Clin Cancer Res. 2004 Oct 1;10(19):6432-6. doi: 10.1158/1078-0432.CCR-04-0893. Clin Cancer Res. 2004. PMID: 15475429 - KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K. Nakayama N, et al. Br J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18. Br J Cancer. 2008. PMID: 19018267 Free PMC article. - Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Liu D, Liu Z, Jiang D, Dackiw AP, Xing M. Liu D, et al. J Clin Endocrinol Metab. 2007 Dec;92(12):4686-95. doi: 10.1210/jc.2007-0097. Epub 2007 Oct 2. J Clin Endocrinol Metab. 2007. PMID: 17911174 - Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S. Della Pepa C, et al. Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Cancer Treat Rev. 2015. PMID: 25573350 Review. - Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P, Walentowicz-Sadłecka M, Grabiec M. Sadłecki P, et al. Ginekol Pol. 2017;88(12):692-697. doi: 10.5603/GP.a2017.0123. Ginekol Pol. 2017. PMID: 29303228 Review.
Cited by
- A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.
Yang MQ, Elnitski L. Yang MQ, et al. PLoS One. 2016 Oct 27;11(10):e0163353. doi: 10.1371/journal.pone.0163353. eCollection 2016. PLoS One. 2016. PMID: 27788148 Free PMC article. - Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Fernández ML, DiMattia GE, Dawson A, Bamford S, Anderson S, Hennessy BT, Anglesio MS, Shepherd TG, Salamanca C, Hoenisch J, Tinker A, Huntsman DG, Carey MS. Fernández ML, et al. Am J Cancer Res. 2016 Oct 1;6(10):2235-2251. eCollection 2016. Am J Cancer Res. 2016. PMID: 27822414 Free PMC article. - Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.
Collinson FJ, Seligmann J, Perren TJ. Collinson FJ, et al. Curr Oncol Rep. 2012 Dec;14(6):509-18. doi: 10.1007/s11912-012-0274-4. Curr Oncol Rep. 2012. PMID: 22948277 Review. - Laminarin-Derived from Brown Algae Suppresses the Growth of Ovarian Cancer Cells via Mitochondrial Dysfunction and ER Stress.
Bae H, Song G, Lee JY, Hong T, Chang MJ, Lim W. Bae H, et al. Mar Drugs. 2020 Mar 9;18(3):152. doi: 10.3390/md18030152. Mar Drugs. 2020. PMID: 32182828 Free PMC article. - JWA gene regulates PANC-1 pancreatic cancer cell behaviors through MEK-ERK1/2 of the MAPK signaling pathway.
Wu YY, Ma TL, Ge ZJ, Lin J, Ding WL, Feng JK, Zhou SJ, Chen GC, Tan YF, Cui GX. Wu YY, et al. Oncol Lett. 2014 Oct;8(4):1859-1863. doi: 10.3892/ol.2014.2329. Epub 2014 Jul 9. Oncol Lett. 2014. PMID: 25202426 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous